Apr 18,2017
Ribo launched a strategic collaboration with global oligonucleotide pharmaceutical giant, Ionis, USA
Suzhou Ribo Life Science Co. Ltd., announced today a partnership with the global oligonucleotide pharmaceutical giant Ionis Pharmaceutical Inc. (Nasdaq code: IONS). Furthermore, it signed cooperation and licensing agreements to work together to promote the R&D and commercialization of oligonucleotide pharmaceuticals (or RNA-targeted drugs) in China.
